A dopamine agonist normalizes serum prolactin (PRL) and shrinks tumor volume, but 10–30% of cases do not undergo remission with the maximum tolerated dose (4–7); these cases are known as dopamine agonist-resistant prolactinomas (8). This evidence concerns the gene PRL and neoplasm.